Remdesivir for the treatment of COVID-19
Kelly Ansems, Felicitas Grundeis, Karolina Dahms, Agata Mikolajewska, Volker Thieme, Vanessa Piechotta, Maria-Inti Metzendorf, Miriam Stegemann, Carina Benstoem, Falk Fichtner
Cochrane Database of Systematic Reviews, doi:10.1002/14651858.cd014962
Trusted evidence. Informed decisions. Better health.
Cochrane
Library Trusted evidence. Informed decisions. Better health.
Cochrane Database of Systematic Reviews Did patients get better with remdesivir? • Remdesivir may have little or no e ect on the length of time patients spent on invasive mechanical ventilation (2 studies, 1298 people). • We do not know whether remdesivir increases or decreases time on supplemental oxygen (3 studies, 1691 people).
Did patients get worse with remdesivir? • We do not know whether patients are more or less likely to need any mechanical ventilation (invasive or non-invasive) with remdesivir (3 studies, 6696 people). • Patients may be less likely to need invasive mechanical ventilation (2 studies, 1159 people). • We do not know whether patients are more or less likely to need non-invasive mechanical ventilation (1 study, 573 people). • We do not know whether patients are more or less likely to need oxygen by mask or nasal prongs (1 study, 138 people) .
Quality of life • None of the included studies reported quality of life.
Unwanted e ects • We do not know whether remdesivir leads to more or fewer unwanted e ects of any level (3 studies, 1674 people) . • Patients are probably less likely to experience serious unwanted e ects with remdesivir than with placebo or standard care (3 studies, 1674 people) . In 1000 people, 63 fewer would experience a serious unwanted e ect compared to placebo or standard care.
What are the limitations of the evidence? We are moderately confident in the..
References
Ader ; Ader, Er-Smadja, Poissy, Bouscambert-Duchamp, Belhadi et al., Antiviral drugs in hospitalised patients with COVID-19 -the DisCoVeRy trial, CLINICALTRIALS.GOV,
doi:10.1101/2021.01.08.20248149
Beigel, Beigel, Tomashek, Dodd, Mehta et al., Remdesivir for the treatment of COVID-19 -final report, New England Journal of Medicine,
doi:10.1056/NEJMoa2007764
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19 -preliminary report, New England Journal of Medicine,
doi:10.1056/NEJMoa2007764
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19 -preliminary report, New England Journal of Medicine,
doi:10.1056/NEJMc2022236
Deresinski, Treatment of COVID-19 patients with remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a
Elliott, Elliot, Chan, Deresinski 2020 {published data only} Deresinski S. Remdesivir and COVID-19
Excel, Microso Corporation ; Moher ; Moher, Liberati, Tetzla, Altman et al., SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology, New England Journal of Medicine,
doi:10.1371/journal.pmed.1000097
Eynde, Consortium. Repurposed antiviral drugs for COVID-19 -interim WHO solidarity trial results, New England Journal of Medicine,
doi:10.3390/ph13050098
Funk, Pharris, Spiteri, Bundle, Melidou et al., Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021, Eurosurveillance,
doi:10.2807/1560-7917.ES.2021.26.16.2100348
Gautret, Million, Jarrot, Jau, Colson et al., Natural history of COVID-19 and therapeutic options, Expert Review of Clinical Immunology,
doi:10.1080/1744666X.2021.1847640
Goldberg, Zvi, Sheena, Sofer, Krause et al., A real-life setting evaluation of the e ect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel,
doi:10.1056/NEJMoa2015301]ISRCTN15874265
Goldman, Goldman, Lye, Hui, Marks et al., Impact of baseline alanine aminotransferase levels on the safety and e icacy of remdesivir in severe COVID-19 patients
Grubaugh, Hanage, Rasmussen, Higgins, Thompson et al., Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear,
doi:10.1016/j.cell.2020.06.040
Hu 2020 Hu, Song, Xu, Chen, Xu, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China, Science China Life Sciences,
doi:10.1007/s11427-020-1661-4
Huang 2020 Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet,
doi:10.1016/S0140-6736(20)30183-5
Kaka 2021 Kaka, Macdonnald, Greer, Vela, Duan-Porter et al., Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points, Annals of Internal Medicine,
doi:10.7326/L21-0130
Karagiannidis, Mostert, Hentschker, Voshaar, Malzahn et al., Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study, Cochrane Database of Systematic Reviews,
doi:10.1016/S2213-2600(20)30316-7
Ko, Remdesivir reduces time to recovery in adults hospitalised with COVID-19: a meaningful step in therapeutic discovery, Journal of Clinical Outcomes Management,
doi:10.1056/NEJMoa2007764]NCT04280705
Lai 2021 Lai, Chen, Wang, Chen, Wang et al., Clinical e icacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomised controlled trials, Journal of Antimicrobial Chemotherapy,
doi:10.1093/jac/dkab093
Li 2020b Li, Geng, Peng, Meng, Lu et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Journal of Pharmaceutical Analysis,
doi:10.1016/j.jpha.2020.03.001
Lo 2017 Lo, Jordan, Arvey, Sudhamsu, Shrivastava-Ranjan et al., GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses, Scientific Reports,
doi:10.1038/srep43395
Malaiyan, Arumugam, Mohan, Malin ; Malin, Suárez et al., An update on the origin of SARS-CoV-2: despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and O-linked glycan residues, Clinical Microbiology Reviews,
doi:10.1002/jmv.26261
Mcguigan, Hassan-Abdallah, Srinivasan, Wang, Siddiqui et al., Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives, Journal of Medicinal Chemistry,
doi:10.1021/jm060776w
Meng ; Meng, Xiong, He, Lin, Hao et al., CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China, Journal of Infection,
doi:10.1016/j.jinf.2020.04.004
O N T R I B U T I O N S O F A U T H O R S Ka ; D E C L A R A T I O N S O F I N T E R, CB: methodological expertise and advice, data extraction and assessment, conception, writing and proofreading of the manuscript. FF: clinical expertise and advice, data extraction and assessment, conception, writing and proofreading of the manuscript
Olalla, Remdesivir for the treatment of COVID-19 -preliminary report, New England Journal of Medicine,
doi:10.1056/NEJMc2022236
Olsen, Henriksen, Kåsine, Lund-Johansen, Hoel, Evaluation of remdesivir and hydroxychloroquine on viral clearance in COVID-19 patients: results from the NOR-solidarity randomised trial, CLINICALTRIALS.GOV,
doi:10.2139/ssrn.3774182
Oran ; Oran, Topol, Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review, Annals of Internal Medicine,
doi:10.7326/M20-3012
Paladugu, Donato, Remdesivir improved time to recovery in adults hospitalised with COVID-19 and lower respiratory tract involvement, Annals of Internal Medicine,
doi:10.7326/ACPJ202007210-005
Pan 2020 Pan, Liu, Wang, Guo, Hao et al., Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, Statistics in Medicine,
doi:10.1001/jama.2020.6130
Pan, Peto, Karim, Alejandria, Henao-Restrepo et al., Repurposed antiviral drugs for COVID-19 -interim WHO solidarity trial results, CLINICALTRIALS.GOV,
doi:10.1101/2020.10.15.20209817
Piechotta, Valk, Chai, Wood, Lamikanra et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area,
doi:10.1371/journal.pone.0243705
Schilling, Lehfeld, Schumacher, Ullrich, Diercke et al., Disease severity of the first COVID-19 wave in Germany using reporting data from the national notification system,
doi:10.25646/7170
Schwarz, Tober-Lau, Hillus, Helbig, Lippert et al., Comparative therapeutic e icacy of remdesivir and combination lopinavir, ritonavir and interferon beta against MERS-CoV, Science Translational Medicine,
doi:10.3201/eid2708.211145
Siegel 2017 Siegel, Hui, Doer Ler, Chun, Zhang, Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the treatment of ebola and emerging viruses, Cochrane Database of Systematic Reviews,
doi:10.1021/acs